Flotillin microdomains, specialized
lipid raft domains in cell membranes, serve as physical platforms for many different molecules important in crucial intracellular signaling pathways.
Flotillin-2 (Flot2), together with
flotillin-1, is a marker for
lipid raft microdomains distinct from caveolar
lipid rafts, and has been implicated in the progression of
cancer and
metastasis formation. Based largely on studies in xenograft models,
flotillin-2 has been implicated in the progression of multiple types of human
tumors, including
breast cancer. In our studies, we identified
flotillin-2 as highly amplified in a high-throughput comparative genomic hybridization screen of human
breast cancer cell lines and
breast tumor samples.
Short hairpin RNA-mediated reduction of
flotillin-2 protein levels significantly reduced the tumorigenicity and metastatic capability of a human
breast cancer cell line in vivo. We generated mice deficient for
flotillin-2 and also found a reduction of
flotillin-1 protein levels and complete absence of
flotillin-specific membrane microdomains in these mice. To examine the role of Flot2 in mammary
tumorigenesis and lung
metastasis, we used an in vivo molecular genetics approach, crossing a well-characterized transgenic mouse model of
breast cancer, the MMTV-PyMT (mouse mammary tumor virus-polyoma middle
T antigen) mouse, with gene-targeted Flot2(-/-) mice.
Flotillin-2 deficiency lead to a striking reduction in the number of lung
metastasis observed, but had no influence on primary
tumor formation in this model. Our results indicate, using a novel in vivo animal model approach, that Flot2 is an important regulator of mammary
tumor-derived lung
metastasis.